JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression-Reference-Cited by-同舟云学术

JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression

Published:2019-09-10 Issue:12 Volume:145 Page:3376-3388
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mohrherr Julian¹²,Haber Marcel²,Breitenecker Kristina¹²,Aigner Petra¹²,Moritsch Stefan³,Voronin Viktor²,Eferl Robert³^ORCID,Moriggl Richard²⁴⁵,Stoiber Dagmar¹²,Győrffy Balázs⁶,Brcic Luka⁷,László Viktória⁸,Döme Balázs⁸⁹¹⁰¹¹,Moldvay Judit¹⁰¹²,Dezső Katalin¹³,Bilban Martin¹⁴¹⁵,Popper Helmut⁷^ORCID,Moll Herwig P.¹^ORCID,Casanova Emilio¹²^ORCID

Affiliation:

1. Department of Physiology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC)Medical University of Vienna Vienna Austria

2. Ludwig Boltzmann Institute for Cancer Research (LBI‐CR) Vienna Austria

3. Institute of Cancer ResearchMedical University of Vienna & Comprehensive Cancer Center (CCC) Vienna Austria

4. Institute of Animal Breeding and GeneticsUniversity of Veterinary Medicine Vienna Austria

5. Medical University of Vienna Vienna Austria

6. MTA TK Lendület Cancer Biomarker Research Group, Institute of Enzymology, and Second Department of PediatricsSemmelweis University Budapest Hungary

7. Diagnostic & Research Institute of PathologyMedical University of Graz Graz Austria

8. Division of Thoracic Surgery, Department of Surgery & Comprehensive Cancer Center (CCC)Medical University of Vienna Vienna Austria

9. Department of Biomedical Imaging and Image‐guided Therapy, Division of Molecular and Gender ImagingMedical University of Vienna Vienna Austria

10. Department of Tumor Biology, National Korányi Institute of PulmonologySemmelweis University Budapest Hungary

11. Department of Thoracic SurgeryNational Institute of Oncology and Semmelweis University Budapest Hungary

12. SE‐NAP Brain Metastasis Research Group, 2nd Department of PathologySemmelweis University Budapest Hungary

13. First Department of Pathology and Experimental Cancer ResearchSemmelweis University Budapest Hungary

14. Department of Laboratory MedicineMedical University of Vienna Vienna Austria

15. Core FacilitiesMedical University of Vienna Vienna Austria

Funder

Austrian Science Fund

National Research, Development and Innovation Fund

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32624

Reference49 articles.

1. Non-small cell lung cancer: current treatment and future advances

2. Comprehensive molecular profiling of lung adenocarcinoma

3. Clinical Implications of Genomic Discoveries in Lung Cancer

4. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1;Cell Death Discovery;2024-08-29

2. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice;Gastric Cancer;2024-05-28

3. The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis;Frontiers in Oncology;2024-04-19

4. CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1;2024-03-05

5. The role of IFN-γ-signalling in response to immune checkpoint blockade therapy;Essays in Biochemistry;2023-09